Biontech Se Sponsored Adr Stock News

BioNTech and Pfizer said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test and they could deliver an Omicron-based vaccine in March 2022 if needed. In the first official statement from vaccine manufacturers on the likely efficacy of

(RTTNews) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) reported results from an initial laboratory study showing that serum antibodies induced by the Pfizer-BioNTech COVID-19 vaccine neutralized the SARS-CoV-2 Omicron variant after three doses. "Although two doses of the vaccine may still offer protection against severe disease caused by the…

MAINZ, Germany, December 8, 2021 BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will hold a digital press conference on Wednesday, December 8, 2021, to present the results from initial laboratory studies which started about two weeks ago. The studies aimed to investigate the effects of the Omicron variant on COVID-19 vaccine-induced immune responses. The press conference will solely be held in a virtual format and will be conducted in English.

New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Pfizer Inc. and BioNTech SE announced on Wednesday that their COVID-19 vaccine has shown a capacity to neutralize the virus'' Omicron variant. The two companies issued a statement, explaining that

Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage), while two doses show significantly reduced ne

(PLX AI) - Pfizer and BioNTech Provide Update on Omicron Variant Pfizer says antibodies from its vaccine neutralize the SARS-CoV-2 Omicron variant after three doses Sera obtained from vaccinees o

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies in

Early lab data released Wednesday suggests a booster shot of the Pfizer-BioNTech vaccine is necessary to ensure protection against omicron, rather than just two doses.

The stock price of BioNTech SE (NASDAQ: BNTX) increased by over 4% pre-market today. This is why it happened.

Yields for U.S. government debt on Wednesday were trading mixed as investors digested news suggesting the omicron variant of coronavirus that causes COVID-19 may not impact the economy as much as fear

A small study in South Africa shows that the omicron variant can partially evade protection from two doses of Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine. But the study did